InnoCan Pharma Corporation (INNO.CN)
| Previous Close | 0.2500 |
| Open | 0.2500 |
| Bid | 0.2450 x N/A |
| Ask | 0.2500 x N/A |
| Day's Range | 0.2500 - 0.2500 |
| 52 Week Range | 0.2100 - 0.5200 |
| Volume | |
| Avg. Volume | 73,762 |
| Market Cap | 70.165M |
| Beta (5Y Monthly) | 3.09 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0200 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
CNW GroupInnocan Pharma Submits Investigational New Animal Drug Application to FDA's Veterinary Center
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that the FDA's Center for Veterinary Medicine (CVM) has granted the Company a sponsor fee waiver and assigned an Investigational New Animal Drug (INAD) number for its LPT-CBD (Liposome Platform Technology-Cannabidiol) product. This represents a significant step for the Company, as an INAD designation facilitates corres
CNW GroupInnocan Pharma Engages Pain Management Expert in Preparation for Upcoming FDA Meeting
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that it has engaged Past-President of the Eastern Pain Association, Dr. William K. Schmidt, to support its LPT-CBD submission process to the FDA for chronic pain.
- CNW Group
Innocan Pharma Announces Successful Preliminary Safety Evaluation of LPT-CBD in Minipigs
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce the success and conclusion of a preliminary safety evaluation of Innocan's single injection and sustained-release LPT-CBD conducted on minipigs. The animals demonstrated excellent drug tolerance and did not exhibit any drug-related adverse events.
